Frank J Hsu

4PUBLICATIONS
77CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Apr 21, 2026
Intratumoral sotigalimab with pembrolizumab induces rapid activation of antigen presenting cells and drives anti-tumor responses in non-injected tumors in metastatic melanoma: A phase I/II study.

|Feb 05, 2025
A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers.

Andrew H Ko, Joseph Chao, Marcus S Noel

|Jan 05, 2024
Neoadjuvant CD40 Agonism Remodels the Tumor Immune Microenvironment in Locally Advanced Esophageal/Gastroesophageal Junction Cancer.

Maira Soto, Erin L Filbert, Hai Yang

|Aug 03, 2023
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy.

Sarah A Weiss, Mario Sznol, Montaser Shaheen

Pageof 1

Frequent Collaborators

2 joint publications

Lawrence Fong

2 joint publications

Bridget P Keenan

2 joint publications

Andrew Ko

2 joint publications

Erin L Filbert